Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

We found no consistent difference in geometric mean nAb titers between mice strains that received 9vHPV at any time point tested or in median HPV16- or HPV18-specific plasma cell frequencies. Thus, we conclude the magnitude and durability of nAb responses to 9vHPV vaccination do not depend on DNA sensing pathways.

P=N/A, N=2500, Not yet recruiting, Indiana University

P2, N=525, Not yet recruiting, Merck Sharp & Dohme LLC

P4, N=17, Active, not recruiting, Emory University | N=44 --> 17

P=N/A, N=34, Terminated, University of Alabama at Birmingham | N=610 --> 34 | Trial completion date: Jun 2026 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jul 2025; Slow pace of recruitment

P4, N=300, Recruiting, Canadian Immunization Research Network | Not yet recruiting --> Recruiting

P4, N=300, Not yet recruiting, Canadian Immunization Research Network

P4, N=1403, Completed, Columbia University | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024

P4, N=100, Recruiting, Emory University | Not yet recruiting --> Recruiting | Trial completion date: May 2028 --> Sep 2028 | Initiation date: May 2025 --> Aug 2025 | Trial primary completion date: May 2028 --> Sep 2028

The 9vHPV vaccine demonstrated robust immunogenicity and encouraging viral clearance rates in MSM with HIV up to 35 years. These findings support extending vaccination beyond 26 years in this high-risk group, emphasizing the additional coverage provided by the 9vHPV formulation.

P3, N=1059, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P1, N=72, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting